Literature DB >> 23983440

Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis.

Lin-Lin Chen1, Yi-You Zou, Fang-Gen Lu, Fu-Jun Li, Guang-Hui Lian.   

Abstract

AIM: To determine the efficacy profiles of different concentrations of Lactobacillus acidophilus (L. acidophilus) for treating colitis using an experimental murine model.
METHODS: Colitis was established in 64 BALB/c mice by adding 5% dextran sodium sulfate (DSS) to the drinking water and allowing ad libitum access for 7 d. The mice were then randomly divided into the following control and experimental model groups (n = 8 each; day 0): untreated model control; negative-treatment model control (administered gavage of 1 mL/10 g normal saline); experimental-treatment models C4-C8 (administered gavage of 10(4), 10(5), 10(6), 10(7), or 10(8) CFU/10 g L. acidophilus, respectively); positive-treatment model control (administration of the anti-inflammatory agent prednisone acetate at 45 μg/10 g). Eight mice given regular water (no DSS) and no subsequent treatments served as the normal control group. Body weight, fecal traits, and presence of fecal occult blood were assessed daily. All animals were sacrificed on post-treatment day 7 to measure colonic length, perform histological scoring, and quantify the major bacteria in the proximal and distal colon. Intergroup differences were determined by one-way ANOVA and post-hoc Student-Newman-Keuls comparison.
RESULTS: All treatments (L. acidophilus and prednisone acetate) protected against colitis-induced weight loss (P < 0.05 vs model and normal control groups). The extent of colitis-induced colonic shortening was significantly reduced by all treatments (prednisone acetate > C4 > C5 > C7 > C8 > C6; P < 0.05 vs untreated model group), and the C6 group showed colonic length similar to that of the normal control group (P > 0.05). The C6 group also had the lowest disease activity index scores among the model groups. The bacterial profiles in the proximal colon were similar between all of the experimental-treatment model groups (all P > 0.05). In contrast, the bacterial profile in the distal colon of the C6 group showed the distinctive features (P < 0.05 vs all other experimental-treatment model groups) of Lactobacillus sp. and Bifidobacterium sp. being the most abundant bacteria and Staphylococcus aureus being the least abundant bacteria.
CONCLUSION: The most therapeutically efficacious concentration of L. acidophilus (10(6) CFU/10 g) may exert its effects by modulating the bacterial profile in the distal colon.

Entities:  

Keywords:  Bifidobacterium; Colonic flora; Efficacy profile; Experimental colitis; Lactobacillus acidophilus; Therapeutic dose

Mesh:

Substances:

Year:  2013        PMID: 23983440      PMCID: PMC3752571          DOI: 10.3748/wjg.v19.i32.5347

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

Authors:  Rodrigo Bibiloni; Richard N Fedorak; Gerald W Tannock; Karen L Madsen; Paolo Gionchetti; Massimo Campieri; Claudio De Simone; R Balfour Sartor
Journal:  Am J Gastroenterol       Date:  2005-07       Impact factor: 10.864

2.  Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice.

Authors:  A Kokesová; L Frolová; M Kverka; D Sokol; P Rossmann; J Bártová; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

3.  A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis.

Authors:  Laura Peran; Saleta Sierra; Mònica Comalada; Federico Lara-Villoslada; Elvira Bailón; Ana Nieto; Angel Concha; Mónica Olivares; Antonio Zarzuelo; Jordi Xaus; Julio Gálvez
Journal:  Br J Nutr       Date:  2007-01       Impact factor: 3.718

4.  Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease.

Authors:  M P Conte; S Schippa; I Zamboni; M Penta; F Chiarini; L Seganti; J Osborn; P Falconieri; O Borrelli; S Cucchiara
Journal:  Gut       Date:  2006-04-28       Impact factor: 23.059

Review 5.  VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.

Authors:  Therese M Chapman; Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.

Authors:  Therese M Chapman; Greg L Plosker; David P Figgitt
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

7.  Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

Authors:  T Kühbacher; S J Ott; U Helwig; T Mimura; F Rizzello; B Kleessen; P Gionchetti; M Blaut; M Campieri; U R Fölsch; M A Kamm; S Schreiber
Journal:  Gut       Date:  2006-01-09       Impact factor: 23.059

8.  Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis.

Authors:  Ryuichi Furuta; Takafumi Ando; Osamu Watanabe; Osamu Maeda; Kazuhiro Ishiguro; Kenji Ina; Kazuo Kusugami; Hidemi Goto
Journal:  J Gastroenterol Hepatol       Date:  2007-02       Impact factor: 4.029

9.  Recombinant probiotic therapy in experimental colitis in mice.

Authors:  R Gardlik; R Palffy; P Celec
Journal:  Folia Biol (Praha)       Date:  2012       Impact factor: 0.906

10.  A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis.

Authors:  L Peran; D Camuesco; M Comalada; E Bailon; A Henriksson; J Xaus; A Zarzuelo; J Galvez
Journal:  J Appl Microbiol       Date:  2007-10       Impact factor: 3.772

View more
  8 in total

1.  Oral supplementation with selected Lactobacillus acidophilus triggers IL-17-dependent innate defense response, activation of innate lymphoid cells type 3 and improves colitis.

Authors:  Jiří Hrdý; Aurélie Couturier-Maillard; Denise Boutillier; Carmen Lapadatescu; Philippe Blanc; Jan Procházka; Bruno Pot; Bernhard Ryffel; Corinne Grangette; Mathias Chamaillard
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

2.  Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis.

Authors:  Linlin Chen; Yiyou Zou; Jie Peng; Fanggen Lu; Yani Yin; Fujun Li; Junwen Yang
Journal:  J Immunol Res       Date:  2015-04-20       Impact factor: 4.818

3.  Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis.

Authors:  Joseph P Zackular; Nielson T Baxter; Grace Y Chen; Patrick D Schloss
Journal:  mSphere       Date:  2015-11-04       Impact factor: 4.389

Review 4.  Probiotic Species in the Modulation of Gut Microbiota: An Overview.

Authors:  Md Abul Kalam Azad; Manobendro Sarker; Tiejun Li; Jie Yin
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

5.  Dose-dependent effects of kefir on colitis induced by trinitrobenzene sulfonic acid in rats.

Authors:  Nurhayat Ozkan Sevencan; Mehmet Isler; Fatma Nilgun Kapucuoglu; Altug Senol; Burcak Kayhan; Sefa Kiztanir; Muhammed Cem Kockar
Journal:  Food Sci Nutr       Date:  2019-08-22       Impact factor: 2.863

6.  Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model.

Authors:  Camille Aubry; Christophe Michon; Florian Chain; Yolande Chvatchenko; Laurence Goffin; Simone C Zimmerli; Sylvia Leguin; Philippe Langella; Luis Bermudez-Humaran; Jean-Marc Chatel
Journal:  Microb Cell Fact       Date:  2015-11-06       Impact factor: 5.328

7.  Different Effects of Three Selected Lactobacillus Strains in Dextran Sulfate Sodium-Induced Colitis in BALB/c Mice.

Authors:  Yi Cui; Hongyun Wei; Fanggen Lu; Xiaowei Liu; Deliang Liu; Li Gu; Chunhui Ouyang
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

Review 8.  Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases.

Authors:  Eddy Owaga; Rong-Hong Hsieh; Beatrice Mugendi; Sakhile Masuku; Chun-Kuang Shih; Jung-Su Chang
Journal:  Int J Mol Sci       Date:  2015-09-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.